Sarcoma News
The daily sarcoma news is a unique cancer news service that evaluates all aspects of sarcoma research and reports on the developments that are most important to cancer patients and health care providers. The daily cancer news provides information about emerging options for sarcoma prevention, early detection and sarcoma treatment, as well as advances in supportive care and personalized medicine. Supportive care improves quality of life by making sarcoma treatment more tolerable, and personalized medicine offers the potential for improved treatment outcomes by using specific characteristics of the patient or the cancer to guide cancer treatment decisions. In addition, interested individuals can search the Cancer Consultants Sarcoma News Archives to find the results of the cancer studies that led to the care they have been offered.
Sarcoma News
Following Lifestyle Recommendations Reduces Risk of Cancer Death (May 15, 2013)
People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying... Continue Reading
Overall cancer death rates continue to decline in both men and women and across major ethnic and racial groups, according to the annual Status of Cancer report published in the Journal of the National... Continue Reading
In patients with localized Ewing sarcoma, chemotherapy administered every two weeks is more effective than chemotherapy administered every three weeks, with no increase in toxicity, according to the results... Continue Reading
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical... Continue Reading
Two million cancer cases each year—or roughly 16 percent of cancers worldwide—are the result of preventable and treatable infections such as human papillomavirus (HPV) and Hepatitis C (HCV), according... Continue Reading
The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first... Continue Reading
In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal... Continue Reading
For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma... Continue Reading
A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing... Continue Reading
In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better... Continue Reading
Latest Sarcoma News By Stage
General
Regorafenib May Expand GIST Treatment Options (June 13, 2012)
Among patients with gastrointestinal stromal tumors (GIST) that worsen in spite of standard treatment, the investigational drug regorafenib delays cancer progression. These results—from a Phase III clinical trial—were presented at the 2012 Annual... Continue Reading
Votrient Approved for the Treatment of Sarcoma (May 7, 2012)The U.S. Food and Drug Administration (FDA) has approved Votrient® (pazopanib) for the treatment of patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. It is the first new drug in decades to treat this type of cancer. Soft... Continue Reading
Longer Treatment with Gleevec Effective Against Gastrointestinal Stromal Tumors (GIST) (April 9, 2012)In a Phase III clinical trial, three years of adjuvant (post-surgery) treatment with Gleevec® (imatinib) resulted in better survival than one year of adjuvant treatment among patients with high-risk gastrointestinal stromal tumors (GIST). These results... Continue Reading
Genetic Change Linked with Rhabdomyosarcoma Survival (April 4, 2012)For children with rhabdomyosarcoma, a test for a specific genetic change could eventually improve risk estimates and treatment decisions. These results were published in the Journal of Clinical Oncology. Rhabdomyosarcoma is a soft-tissue cancer that arises... Continue Reading
FDA Updates Use of Gleevec for Gastrointestinal Stromal Tumors (February 29, 2012)In changes approved by the US Food and Drug Administration (FDA), the prescribing information for Gleevec® (imatinib) now notes that three years of adjuvant (post-surgery) treatment results in better survival than one year of adjuvant treatment among... Continue Reading
More General
